Aprea Therapeutics, Inc. (APRE)
R&D Expense Growth
52.81%
Quarterly · Period ending:
APRE R&D Expense Growth
Latest reported52.81%period ending
Latest reported52.81%period ending
APRE Quarterly R&D Growth (QoQ) (0.00% → 52.81%)
Latest values, visible window
High-resolution chart · PNG
APRE r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 52.8111% | |
| 59.7051% | |
| -38.4448% | |
| -14.2921% | |
| -22.9898% | |
| 5.2554% | |
| -17.1203% | |
| 11.2884% | |
| 59.8177% | |
| -21.7685% | |
| -3.6236% | |
| -3.6344% | |
| 75.2951% | |
| 136.4561% | |
| -52.4501% | |
| -98.6508% | |
| 1,925.4367% | |
| -8.3497% | |
| -25.8238% | |
| -9.5975% | |
| -1.6202% | |
| -27.4894% | |
| 6.4716% | |
| -18.0749% | |
| 17.5669% | |
| 13.1078% | |
| 63.7744% | |
| 13.6715% | |
| 17.4362% | |
| -16.3024% | |
| 90.5019% | |
| 0% |